Here are four key points from their growth strategy:
• For the company as a whole, the management board expects sales to total between $37.6 million and $39.9 million.
• The company forecasts EBITDA in the financial year 2015 of between $2.8 million and $3.9 million.
• For the full year 2015 the company anticipates trauma sales growth to be between $16.9 million and $17.5 million. Its LOQTEQ product family is expected to be the main driver of this development.
• Sales in the biomaterials business are expected to grow by 10 percent.
The company is also still in talks with selected strategic investors and private equity companies on a transaction for aap Biomaterials that is anticipated in the first quarter of 2015.
More articles on devices:
27 spine devices receive FDA 510(k) clearance in January
MiMedx withdraws complaint against Organogenesis
NuVasive COO sells 15k shares — 5 things to know
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
